Question 1

What is the catalog number for BIRC8?

Accepted Answer

The catalog number for BIRC8 is MBS8563223.

Question 2

What sizes are available for BIRC8?

Accepted Answer

BIRC8 is available in the following size(s): 0.2 mL, 0.1 mL (AF405L), 0.1 mL (AF405S), 0.1 mL (AF610), 0.1 mL (AF635), 0.1 mL (APC), 0.1 mL (Cy3), 0.1 mL (Cy5), 0.1 mL (Cy5.5), 0.1 mL (Cy7), 0.1 mL (PE), 0.1 mL (AF546), 0.1 mL (AF405M), 0.1 mL (AF750), 0.1 mL (Biotin), 0.1 mL (HRP), 0.1 mL (FITC), 0.1 mL (AF350), 0.1 mL (AF488), 0.1 mL (AF555).

Question 3

How many pack sizes does BIRC8 come in?

Accepted Answer

BIRC8 is available in 20 different pack sizes.

Question 4

Is BIRC8 in stock?

Accepted Answer

BIRC8 is currently made to order / not held in immediate stock. Contact us for lead time.

Question 5

Do you offer custom or private-label production of this type of product?

Accepted Answer

Yes, custom antibody development and private-label production services are available. Contact our sales team to discuss your target, timeline, and quantity requirements.

Question 6

What is the immunogen used to generate this antibody?

Accepted Answer

Immunogen or antigen details used to raise this antibody are listed on the product datasheet under immunogen information.

Question 7

What is the recommended positive control for this assay?

Accepted Answer

A recommended positive control, where one is specified by the manufacturer, is listed on the datasheet or in the assay protocol.

BIRC8

Product Specifications

Gene Name

NCBI Gene ID

Reactivity

Other Gene Names

Short Name

Other Product Names

NCBI GI Number

NCBI Accession Number

Available Sizes

Frequently Asked Questions

Explore Other Products

TRNAT13 Protein Vector (Human) (pPM-C-HA)

MAPK8 (JNK1, PRKM8, SAPK1, SAPK1C, Mitogen-activated Protein Kinase 8, MAP Kinase 8, MAPK 8, JNK-46, Stress-activated Protein Kinase 1c, Stress-activated Protein Kinase JNK1, c-Jun N-terminal Kinase 1) (MaxLight 650)

TRAILR2 Antibody / TRAIL Receptor 2 / DR5

Sibrotuzumab

Sibrotuzumab

Sibrotuzumab